The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine) 50 milligram oral tablets, a groundbreaking ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain.Journavx received FDA ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...